However, multiple adverse effects undermine the use of this class of drugs in most chronic pain cases. 3 Furthermore, like with other classes of drugs, not all pain modalities are equally responsive to a particular opioid. 4, 5 Therefore, further efforts toward the discovery of safe and effective opioid therapeutics for multimodal chronic pain treatment are urgently needed. Recent advances suggest that opioids with mixed mu/delta-opioid receptor (μ/δ-OR) activity demonstrate a potential therapeutic alternative to traditional μ-OR-selective agonists. 6 The present study is part of our continuing efforts aimed at providing complete preclinical characterization of one such opioid, morphine-6-O-sulfate (M6S).
RATIONALE
M6S was initially synthesized as a part of a study on morphine 3-and 6-O-glucuronides, ethereal sulfates, and phosphate conjugates. 7 It was quickly established and confirmed in vivo that M6S was more potent than morphine in the radiant-heat tail flick test (TFL; superficial burning pain [8] [9] [10] [11] ). Furthermore, it was reported 11 that compared with morphine, M6S: (1) is more potent in the alleviation of deep pressure or superficial mechanical pain in the chronic constriction nerve injury rat model of mononeuropathy and in alleviating spontaneous pain in the rat model of formalin-induced inflammation; (2) demonstrates delayed development of tolerance during chronic treatment (TFL); and (3) when compared with morphine has a superior therapeutic window, as determined by motor coordination and gastric transit tests in normal rats. In efforts to explain these observations, 11 previous studies have suggested that unlike the pure μ-OR agonist morphine, M6S may act through both μ-and δ-ORs. 8, [12] [13] [14] Although mixed µ/δ-agonists other than M6S also have demonstrated potent antinociceptive action and an improved tolerance profile when compared with morphine, [15] [16] [17] [18] M6S holds unique promise for future clinical applications because it is the easiest of the known mixed µ/δ-agonists to prepare from the readily available opium alkaloid, morphine. 13 However, despite this promise, multiple preclinical studies with M6S remain to BACKGROUND: Morphine-6-O-sulfate (M6S) is a mixed μ/δ-opioid receptor (OR) agonist and potential alternative to morphine for treatment of chronic multimodal pain. METHODS: To provide more support for this hypothesis, the antinociceptive effects of M6S and morphine were compared in tests that access a range of pain modalities, including hot plate threshold (HPT), pinprick sensitivity threshold (PST) and paw pressure threshold tests. RESULTS: Acutely, M6S was 2-to 3-fold more potent than morphine in HPT and PST tests, specifically, derived from best-fit analysis of dose-response relationships of morphine/M6S half-effective dose (ED 50 ) ratios (lower, upper 95% confidence interval [CI]) were 2.8 (2.0-5.8) in HPT and 2.2 (2.1, 2.4) in PST tests. No differences in analgesic drug potencies were detected in the PPT test (morphine/M6S ED 50 ratio 1.2 (95% CI, 0.8-1.4). After 7 to 9 days of chronic treatment, tolerance developed to the antinociceptive effects of morphine, but not to M6S, in all 3 pain tests. Morphine-tolerant rats were not crosstolerant to M6S. The antinociceptive effects of M6S were not sensitive to κ-OR antagonists. However, the δ-OR antagonist, naltrindole, blocked M6S-induced antinociception by 55% ± 4% (95% CI, in the HPT test, 94% ± 4% (95% CI, 84-105) in the PST test, and 5% ± 17% (95% CI, −47 to 59) or 51% ± 14% (95% CI, 14-84; 6 rats per each group) in the paw pressure threshold test when examined acutely or after 7 days of chronic treatment, respectively. CONCLUSIONS: Activity via δ-ORs thus appears to be an important determinant of M6S action. M6S also exhibited favorable antinociceptive and tolerance profiles compared with morphine in 3 different antinociceptive assays, indicating that M6S may serve as a useful alternative for rotation in morphine-tolerant subjects. (Anesth Analg 2017;125:1021- 31) Evaluation of Analgesia, Tolerance, and the Mechanism of Action of Morphine-6-O-Sulfate Across Multiple Pain Modalities in Sprague-Dawley Rats be conducted. In this respect, considering the current status of preclinical development of M6S, most studies conducted to date have only compared the ability of morphine and M6S to relieve burning pain in the TFL test [8] [9] [10] [11] 14 ; and the evidence that M6S might be also useful for treating multimodal pain comes from only a single study. 11 Furthermore, little or nothing is known concerning the progression of tolerance or crosstolerance to M6S action or the potential for development of opioid-induced hyperalgesia (OIH) in different pain assays after chronic administration. Finally, although an important role for δ-ORs in the mechanism of action of M6S for amelioration of superficial burning pain appears to be firmly established, 14 potential involvement of δ-ORs in pain control by M6S involving other pain pathways has not yet been determined.
OBJECTIVES
The current study was designed to investigate the role of different OR subtypes in mediating the antinociceptive actions of M6S in several pain modalities. Three evoked pain modalities (evoked superficial burning, pricking, and deep tissue pressure pain; most frequently exaggerated evoked pain modalities in human subjects with diagnosed neuropathic pain 19 ) were assessed in rats after acute and chronic M6S treatment protocols.
METHODS Animals
All animal procedures were approved by the Institutional Animal Care and Use Committee of the University of Arkansas for Medical Sciences and performed in compliance with the guidelines of the National Institutes of Health's Guide for the Care and Use of Laboratory Animals. Male, Sprague-Dawley rats (250-350 g; Charles River Laboratories, Wilmington, MA) were housed 3 per cage with free access to food and water in the animal facility maintained by the University of Arkansas for Medical Sciences Division of Laboratory Animal Medicine. Rats were randomly assigned to specific drug or vehicle treatment groups (6-12 rats per group).
Drugs
Drugs used in this study were morphine hydrochloride (Merck & Co, Inc, Rahway, NJ); M6S (sodium salt, prepared in our laboratory as described previously 13 ); the δ-OR selective antagonist naltrindole (NLD) hydrochloride (Tocris Biosciences, Minneapolis, MN); the κ-OR selective antagonist norbinaltorphimine (nor-BNI) hydrochloride (a generous gift from Dr Philip Portoghese, University of Minnesota, Minneapolis, MN): and nonselective opioid antagonist naltrexone (NTX) hydrochloride (Sigma Aldrich, St Louis, MO). All drugs were prepared in physiological saline immediately before use. The volume of IP injections for all animals was 2 mL/kg of rat body weight. The control group of animals received an equivalent volume of the vehicle only. Treatment of animals with OR antagonists was conducted as described previously. Drugs were injected IP 30 minutes (NTX 2 mg/kg 14, 20 ; NLD 1 mg/ kg) 14, 21 or 18 hours (nor-BNI 5 mg/kg) 14, 22 before the time of peak antinociceptive effect of M6S or morphine.
Antinociceptive Assays
Antinociceptive testing was conducted between 10 am and 5 pm. Animals were allowed to acclimate to the laboratory environment for at least 1 hour before the onset of testing. At least 1 training session was conducted to familiarize rats with the test procedures.
In all the experiments, the pain thresholds were recorded 1 hour before treatment (baseline) and then at 15-to 60-minute intervals after drug injection. In dose-response studies, the same animals were used to test the effect of low-to-moderate doses (0.1-1.0 mg/kg) of morphine or M6S. Drugs were administered in an escalating sequence from low to higher doses with a 2-day washout period between treatments. A 2-day washout period has been shown to be sufficient for complete recovery from the effects of previously administered opioids in oral doses as high as 64 mg/kg. 23 Effects of higher doses (1.5-10 mg/kg) were studied using independent groups of 6 to 12 rats. Studies with animals treated with the 1.5-mg/kg dose were then continued utilizing the same daily dose in chronic, daily treatment studies.
Hot Plate Threshold Assay. Hot plate threshold (HPT) was measured using an IITC Life Sciences incremental hot-plate apparatus (Model PE-34; Woodland Hills, CA) according to a previously described standard protocol. 24 During the test, the plate temperature was increased at a linear rate of 5°C/ min from 35°C baseline to a cutoff temperature of 55°C. The HPT was defined as the temperature at which the animal abruptly withdrew either hind paw from the plate and licked it. Test sessions continued at 10-minute intervals until 3 determinations were made for each animal. The average of these 3 determinations was used for statistical analyses.
Pinprick Sensitivity Threshold Assay. Pinprick sensitivity threshold (PST) was measured using a sewing needle (150-ìm tip with a 30° angle) attached to a handheld force transducer (FORT1000; World Precision Instruments, Inc, Sarasota, FL). Force transducer-generated signals (pinprick force waveforms) were recorded using a differential amplifier (ISO-80; World Precision Instruments) digitized at 50-Hz sampling rate using a Micro 1401 analog-to-digital converter. Threshold recordings were analyzed using Signal-4 software (Cambridge Electronic Design, Cambridge, UK). Rats were placed in an elevated test cage with a wire mesh bottom and allowed to acclimate for 15 minutes. During a test session, 6 pinprick stimuli (trials) were administered to the central ventral aspect of each hind paw with care taken not to apply the probe to locations within the tested area more than once. The intertrial rate was 2 to 6 seconds. The PST force was defined as peak force in grams that produced withdrawal of the hind paw or a maximum 50-g cutoff value for trials in which animals failed to demonstrate a withdrawal response. PST readings (total of 12/rat/test) were filtered for outliers using the mean ± standard deviation (SD) rule; remaining values were averaged and used for the analysis.
Paw Pressure Threshold Assay. Paw pressure threshold (PPT) was measured with a Randall-Selitto analgesia meter as described previously. 24 Each test session consisted of 3 to 5 trials conducted at 5-minute intervals on both hind paws (total of 6-10 trials per rat). In each trial, pressure was applied to the center of the hind paw at a linearly increasing rate of 16 g/s until the animal struggled to withdraw or succeeded in withdrawing its paw. The pressure cutoff was set at 250 g. The nociceptive pain thresholds (in mass units [g] ) were recorded and filtered for outliers using the mean ± SD rule; remaining values were averaged and used for the analysis.
Statistical Analyses
All drug effects in this study are presented in the text and figures in absolute threshold change units or as a percent of absolute peak of the antinociceptive effect (mean ± standard error of mean). All data were checked for normality of distribution. Nonparametric statistical tests were used to statistically compare data that were not normally distributed. Normally distributed data were analyzed by using a 2-way analysis of variance (ANOVA) followed by a post hoc Bonferroni test or a 1-way ANOVA followed by a post hoc Tukey test. The repeated-measures ANOVA was used as appropriate (Graphpad Prism, 5.0, La Jolla, CA). When a statistically significant between-factor interaction was detected by a 2-way ANOVA, the focus of the analysis was on results of post hoc comparisons instead of main effects. In situations in which no interactions were detected, no collapsing data over time or over drug concentration were made, because a priori we were interested in the analysis of the antinociceptive effect of each particular concentration of the drug and in each specific time point of treatment. When only 2 groups were compared, a Student t test was used. Regression analysis and nonlinear curve-fitting procedures were performed using the Origin 6.0 software package (MicroCal, Northampton, MA). Effects were considered as statistically significant at P < .05 corrected for the multiple comparisons using Tukey or Bonferroni correction (Graphpad Prism, 5.0).
Sample Size Justification and Power Analysis. The primary goal of this study was to establish whether M6S produces physiologically meaningful antinociception in a given pain test. We defined physiologically meaningful antinociception as an increase in pain threshold of 1.96 SD (effect size = 1.96) from baseline: 1.2°C, 44.8 g, and 4.4 g in HPT, PPT, and PST tests, respectively. Control population mean ± 1.96 SD value is accepted as a cutoff for the diagnosis of hyper-and hypoalgesia in human-evoked pain studies. 19 Using G*Power 3.1 software (University of Düsseldorf, Germany), 25 we estimated that with this effect size, 6 animals (number of animals per group in most of the experiments in our study) were sufficient to detect drug effects in any statistical test used in this study at an α value of .05 with a power of 0.85 or greater.
RESULTS

Hot Plate Threshold Assay
Baseline HPT values averaged 46.7°C ± 0.1°C (n = 91). No statistically significant changes in HPT values were observed after vehicle treatment, indicating that repeated HPT testing was not associated with accommodation or sensitization ( Figure 1A , triangles). Treatment with either morphine or M6S resulted in statistically significant increases in HPT. However, the effect of M6S was greater ( Figure 1A ) and lasted longer than that of morphine ( Figure 1B ; asterisk).
HPT Dose-Response Curves. For both morphine and M6S, over the dose range tested (0.1-5.6 mg/kg), dose-response relationships could be described by a single-component sigmoidal curve. Comparison of these relationships shows that M6S was approximately 3 times more potent and 1.4 times more efficacious than morphine ( Figure 1C ). The 10-mg/ kg dose of both M6S and morphine produced a much larger increase in HPT approaching the test cutoff value (3.5°C), which was well above the best-fit maximum values determined by the sigmoidal curve-fitting procedure ( Figure 1C , at arrow). These observations suggest existence of a second, low-potency component of HPT analgesia produced by M6S and morphine. This component likely represents effects of sedation rather than activation of an additional antinociceptive pathway. Indeed, for both morphine and M6S, the "sedative" component in the HPT test was observed at drug doses higher than 5.6 mg/kg, which are similar to ED 50 values for sedative effects reported for morphine on locomotor activity and Rotarod tests in rats (5.8-7.4 mg/kg 11, 26, 27 ). Analysis of area under the curve values confirmed that M6S produces a greater total antinociceptive score than morphine in the HPT test ( Figure 1D ).
Tolerance and Crosstolerance Studies. In acute treatment experiments, the peak effects of 1.5 mg/kg morphine or M6S on HPT did not differ (difference −0.36°C ± 0.18°C; 95% confidence interval [CI], −0.74°C to 0.01°C; 12 rats per group; P = 0.0578; unpaired t test). Furthermore, at this concentration, both drugs produced near maximal effects (84% for morphine and 90% for M6S of the respective maximum antinociceptive effects predicted by best-fit of dose-response relationships; Figure 1C ). Thus, these minimal, but efficacious, drug doses were used in the tolerance and crosstolerance studies described subsequently. Drugs were administered once daily, whereas HPT was measured before (baseline) and at 1 to 1.5 hours after injection (the approximate time of peak analgesia) on days 3, 5, 7, and 9 of treatment. Chronic treatment did not alter baseline HPT values in vehicle-and morphine-treated rats. Baseline HPT, however, decreased by approximately 1°C (~2.5%) in rats treated daily with M6S ( Figure 2A , asterisks). In contrast to M6S, rats chronically treated with morphine developed antinociceptive tolerance in the HPT test ( Figure 2B ). Development of morphine/M6S crosstolerance in the HPT test was not observed ( Figure 2B , gray column).
Role of Opioid Receptors. Pretreatment of rats with the relatively nonselective OR antagonist NTX completely antagonized the effects of morphine and M6S in the HPT test, demonstrating that both drugs acted via ORs (data not shown). However, although pretreatment with either the selective κ-opioid antagonist nor-BNI or the selective δ-opioid antagonist NLD did not diminish the antinociceptive effect of morphine in the HPT tests, pretreatment with NLD, but not nor-BNI, reduced the antinociceptive effects of M6S by 45% ( Figure 2C ; asterisk).
Paw Pressure Threshold Assay
The mean baseline value observed in the PPT test was 120 ± 9.6 g (n = 122). Time-profile studies revealed no significant differences between the antinociceptive effects of M6S and morphine www.anesthesia-analgesia.org ANESTHESIA & ANALGESIA (5.6 mg/kg) at any time point examined. For both drugs, antinociceptive effects peaked between 30 and 60 minutes and then declined to below baseline values by 240 and 270 minutes after injection ( Figure 3A) . Analysis of vehicle-treated rats and vehicle-corrected M6S and morphine data suggested that this "hyperalgesia-like" effect occurring at the longer time points in the PPT test is likely the result of potential "sensitization" or "learning" during the repeated test procedure ( Figure 3B ).
PPT Dose-Response Curves. Both morphine and M6S produced similar dose-related antinociception in the PPT test ( Figure 3C ). As observed in the HPT assay, the highest dose of morphine and M6S tested (10 mg/kg) produced greater effects than the plateau observed for the 1.5-and 5.6-mg/kg doses of these compounds. As such, this dose was excluded from the curve-fitting analysis ( Figure 3C , arrow). Like in the time-course and dose-response studies, morphine and M6S afforded similar total antinociceptive scores, as measured by area under the curve ( Figure 3D ).
Tolerance and Crosstolerance Studies. For studies involving chronic treatment, baseline PPT values remained stable in vehicle-treated rats, but decreased by day 7 in rats chronically treated with either morphine or M6S ( Figure 4A ; asterisks). Over the same time period, complete tolerance developed to the antinociceptive effects of morphine in the PPT test. In marked contrast, the antinociceptive effects of M6S did not differ between different days of the study ( Figure 4B ). In morphine/M6S crosstolerance studies, less tolerance (50%-60%; Figure 4B , gray column) was observed with M6S in rats chronically treated with morphine than to morphine in M6S chronically treated animals.
Role of Opioid Receptors. Pretreatment with the δ-selective opioid antagonist NLD (1 mg/kg) had no effect on M6S-induced antinociception in the PPT test when examined acutely, but decreased analgesia by 55% ± 10% in chronically treated animals ( Figure 4C, asterisk) . Pretreatment with the κ-selective opioid antagonist nor-BNI (5 mg/kg, IP) was not tested in PPT experiments with M6S after acute administration. However, pretreatment with nor-BNI had no effect on antinociception produced by M6S in the PPT test in chronic treatment studies ( Figure 4C ).
Pinprick Sensitivity Threshold Assay
The mean PST value measured at baseline was 10.2 ± 0.7 g (n = 38). Repeated testing in vehicle-treated rats did not change baseline PST (Figure 5A, triangles) . The effects of acute treatment with M6S and morphine (5.6 mg/kg) were markedly different. Morphine produced a weak and transient increase in PST (antinociception) followed by a distinct and prolonged phase of hypersensitivity/hyperalgesia (decrease in PST below baseline; Figure 5 , A and B, opened circles), whereas treatment with M6S resulted in antinociception only ( Figure 5, A and B ; closed circles).
PST Dose-Response Curves. The analysis of dose-response relationships demonstrated that M6S was approximately 2-fold more potent and efficacious than morphine as an analgesic in the PST test ( Figure 5C ). Differences between the effect of M6S and morphine on PST were even more pronounced when total antinociceptive scores (area under the curve) were considered ( Figure 5D ). Furthermore, although the total antinociceptive effect of M6S as measured by the area under the curve could be fitted to a sigmoidal curve (adjusted R 2 = 0.998), the antinociceptive and apparent pronociceptive effects of morphine were best fit by linear regression ( Figure 5D ). Furthermore, unlike what was observed in the HPT and PPT tests (see Figures 2C  and 4C ; 10-mg/kg drug dose), no indication of a sedative component was observed in PST dose-relationship studies with either M6S or morphine ( Figure 5C ).
Tolerance and Crosstolerance Studies. For consistency with previously described chronic treatment studies, a 1.5-mg/ kg dose of morphine and M6S was used for chronic drug administration in the PST studies. Baseline PST values did not change over the 7-day injection schedule in vehicletreated animals, but decreased by approximately 20% in both morphine-and M6S-treated rats ( Figure 6A, asterisks) . As observed acutely, morphine was ineffective in the PST test, whereas M6S maintained high efficacy throughout the entire Figure 2 . Chronic treatment effects of morphine and M6S and effects of δ-and κ-OR-specific antagonists on M6S antinociception in the HPT assay. A, Baseline thresholds are expressed as percentages of respective first-day baseline HPT values in rats chronically treated with vehicle, morphine, and M6S (open, light, and dark gray bars, respectively). Two-way RM ANOVA detected statistically significant (P < .05) main effects of treatment, time, and interaction between main effects. However, Bonferoni post hoc test detected a statistically significant difference between day 1 versus day 3, 7, or 9 baseline HPT in M6S-treated rats only (P < .01; 6 rats per group). Compared with the effect of M6S produced on day 1, effects measured on day 3, 7, and 9 were weaker by −0.98 (95% CI, −1.90 to −0.07), −1.05 (95% CI, −1.96 to −0.14), and −1.27 (95% CI, −2.18 to −0.35) ˚C of the HPT change, respectively. In morphine-or vehicle-treated rats, differences of baseline HPT on different days of the study never exceeded 0.38˚C (95% CI, −1.49 to 0.74; day 1 vs day 3 baseline HPT difference observed in vehicle-treated rats). B, Relative (% of the first day) analgesic effects of M6S (solid circles and solid lines) and morphine (open circles and dotted lines) on HPT during chronic daily treatment protocol. Two-way RM ANOVA detected statistically significant (P < .05) main effects of treatment, time, and interaction between main effects. However, statistically significant (P < .01, asterisks) development of tolerance to the antinociceptive effect was observed in morphinebut not M6S-treated rats (Bonferroni post hoc test; mean differences of effects of morphine on day 1 vs day 3, 7, and 9 were . For M6S, the largest difference in the drug effects on HPT was observed between days 1 and day 9 of treatment (17.3% with 95% CI, −48.0%-82.5%). Treatment of morphine-tolerant rats with 1.5 mg/kg M6S (dark gray bar) resulted an antinociceptive effect of M6S that was indistinguishable from that observed in either acute or chronic M6S-HPT studies (1-way ANOVA, F[2,17] = 0.0306, P = .969; 6 rats per group). No differences in M6S effects on HPT (in °C of HPT change) were detected when morphine/M6S replacement and acute M6S treatment groups of animals were compared (95% CI, −0.61 to 0.61) and this difference constituted just 0.05˚C (95% CI, −0.66 to 0.56) for morphine/M6S replacement and chronic M6S treatment groups (Tukey's multiple comparison post hoc test). C, Percent maximum effect on HPT for morphine and M6S alone or after pretreatment with δ-or κ-OR-specific antagonists naltrindole (NLD, 1 mg/kg, IP) or norbinaltorphimine (nor-BNI, 5 mg/kg, IP). Asterisks indicate statistically significant difference between M6S and M6S +NLD rat groups (1-way ANOVA, F(3,23) = 9.353; P =.0005) The mean difference of relative effects of M6S given alone or after pretreatment with NLD was 57% (95% CI, 23.9%-91.0%; P < .01); the same value for morphine was 10% (95% CI, −24.0% to 43.1%; P > .05; post hoc Tukey test; 6 rats per group). ANOVA indicates analysis of variance; nor-BNI, nor binaltorphimine hydrochloride; CI, confidence interval; HPT, hot plate threshold; M6S, morphine-6-O-sulfate; NLD, naltrindole hydrochloride; RM, repeated-measures.
www.anesthesia-analgesia.org ANESTHESIA & ANALGESIA 7-day chronic treatment period ( Figure 6B ). Administration of M6S to morphine-tolerant rats (1.5 mg/kg) resulted in an increase in PST that was not statistically different from that produced by the same dose of M6S in either the acute or the chronic M6S treatment studies ( Figure 6B, column) .
Role of Opioid Receptors. Pretreatment with the selective δ-opioid antagonist NLD (1 mg/kg, i.p.) decreased the antinociceptive effect of M6S in the PST test by approximately 95% (Figure 6C, asterisk) . In contrast, pretreatment with the selective κ-opioid antagonist, nor-BNI, did not alter antinociception produced by M6S in this pain assay ( Figure 6C ).
DISCUSSION
This study is the first to directly compare antinociception produced by M6S and morphine in 3 distinct evoked pain modalities (superficial burning, pricking, and deep pressure pain). Among others, these 3 evoked pain modalities are most frequently exaggerated in human subjects with neuropathy and therefore are of specific interest with regard to development of novel drug treatments. 19 With regard to endpoints measured and neuronal circuitry involved in each test, PST and PPT are thresholds of simple withdrawal reactions, evoking a minimal supraspinal involvement. In this respect, PST and PPT most resemble thresholds to pinprick and blunt pressure pain in humans. 19, 28 In contrast, the HPT test uses paw withdrawal and licking as endpoints, evokes much greater supraspinal involvement, and is more representative of heat pain tolerance than threshold detection. 29 A summary of results from this study is presented in Table  1 . The effects of morphine and M6S were compared using 6 different categories of potential clinical relevance: (1) potency; (2) efficacy; (3) duration of action; (4) development of tolerance; (5) development of acute hyperalgesia; and (6) development of chronic OIH. Based on the data presented, an arbitrary "superiority score" was calculated for each pain modality and is presented as a fraction of categories listed previously in which M6S exhibited "more desirable" characteristics than morphine compared with the total number of categories examined. "More desirable" was defined as traits that would be expected to confer clinical advantage such as greater potency, longer duration of action and higher efficacy, and lower degree of OIH or tolerance (Table 1 , last column). Additionally, information concerning the efficacy of M6S as a potential rotation drug in morphine-tolerant subjects (crosstolerance) and estimates of the involvement of δ-OR-mediated effects in M6S-produced analgesia are listed for each pain modality.
In support of the reports of pain pathway/modality-specific action of analgesic drugs, 4, 30, 31 data from the current study demonstrate distinct antinociceptive effects for both M6S and morphine across the pain modalities tested. However, in each test, M6S scored better than morphine with the rank order of analgesic superiority scores for M6S versus morphine being PST > HPT > PPT (80%, 50%, and 17%, respectively; Table 1 ). Strikingly, this rank order correlated well with the involvement of the δ-OR in M6S action in these tests, that is, PST > HPT > PPT (95%, 55%, and 5%, respectively). Furthermore, the "recovery from tolerance" in the PPT test in rats treated chronically with M6S ( Figure 4B ) also occurred in apparent association with an increase in the involvement of δ-ORs in the antinociceptive effect of M6S (from 5% to approximately 55% on day 1 and day 7 of treatment). Nevertheless, we acknowledge that further research is needed to assess whether tolerance to the antinociceptive effect of M6S in the PPT tests develops during first days of chronic treatment. These correlations agree with observations that morphine acts primarily as a pure μ-OR agonist at clinically relevant concentrations, 32 whereas analgesia produced by M6S appears to involve activation of both μ-and δ-ORs. 8, 9, 13, 14 Indeed, coactivation of μ-and δ-ORs has been reported to enhance the analgesic/antinociceptive efficacy of opioids in vivo. 15, 16, 18, 33 Furthermore, recruitment of δ-ORs to the neuronal membrane surface has been reported to enhance analgesic efficacy of δ-OR agonists in animals chronically treated with μ-OR agonists. [34] [35] [36] Finally, analgesic tolerance develops more slowly after chronic treatment with mixed μ/δ-agonists when compared with that after chronic morphine treatment. 15, 16, 18 In addition to the development of tolerance, acute and chronic OIH constitutes another important limitation for the chronic use of opioids. 37 We observed the development of acute OIH in the PST test in morphine-but not in M6S-treated rats ( Figure 5, A and B) . Chronic OIH (steady decline in baseline pain threshold), however, was a more frequently observed phenomenon in our experiments. Development of chronic OIH was observed in the HPT test during chronic treatment with M6S ( Figure 2A ) and in the PST and PPT tests during chronic treatment with either morphine or M6S (Figures 4A and 6A) . The mechanisms responsible for the development of OIH remain unclear. 37 Nonetheless, our data suggest that mixed μ/δ-OR agonists are unlikely to offer distinct advantages over μ-OR agonists with respect to development of chronic OIH. Another important observation reported in this current study is that for every pain modality examined, tolerance, or lack thereof, was observed regardless of the presence or absence of either acute or chronic OIH. This dissociation is not in accord with the hypothesis that OIH and tolerance to opioids are interlinked phenomena. 38 Furthermore, it suggests that different mechanisms may underlie acute and chronic OIH.
Differences in antinociceptive potency and efficacy of opioids in controlling various pain modalities may be associated Figure 4 . Chronic treatment effects of morphine and M6S and effect of δ-and κ-OR-specific antagonists on M6S antinociception in the PPT assay. A, Baseline thresholds expressed as percentages of respective first day baseline PPT values in rats chronically treated with vehicle, morphine, or M6S (open, light, and dark gray bars, respectively). Two-way RM ANOVA detected main effect of time; F(3,66) = 5.44, P = .002), but no interaction between the factors or the significant effects of treatment were observed. Nonetheless, the baseline PPT in rats chronically treated with morphine and M6S was statistically lower on day 7 than on day 1 (asterisks, Bonferroni post hoc test; P < .01; 6 rats per group). This difference constituted −15.5% (95% CI, −32.7 to 0.86) in morphine-treated rats and −18.4% (95% CI, −34.7 to −2.1) in M6S-treated rats. B, Relative (% of the first day value) analgesic effects of M6S (solid circles and solid lines) and morphine (open circles and dotted lines) on PPT during chronic daily treatment protocol. A 2-way RM ANOVA revealed a significant (P < .05) effect of time and time × treatment interaction. A Bonferroni post hoc test detected decreased antinociception on days 5 and 7 (compared with day 1 respective mean differences were −34.2% [95% CI, −63 to −5.2]) and −38.9% (95% CI, −67.9 to −9.9, asterisks; P < .05) in rats treated with morphine, but not with M6S. In the latter group, the largest relative decline in the antinociceptive action of M6S was observed on day 3 of the experiment, but did not reach statistical significance: −23.0% (95% CI, −52.0 to 5.9). Treatment of morphine-tolerant rats with 1.5 mg/kg M6S (dark gray bar) resulted in a weakened (50%-60% of observed in experiments with either acute or day 7 chronic treatment) antinociceptive effect of M6S. This decrease, however, was not statistically significant; Kruskal-Wallis test followed by Dunn's multiple comparison post hoc test; 12 rats per group). C, Percent maximum effect on PPT for M6S alone or after pretreatment with δ-or κ-OR-specific antagonists: naltrindole (NLD, 1 mg/kg, IP) or norbinaltorphimine (nor-BNI, 5 mg/kg, IP). Asterisks indicates statistically significant difference between M6S and M6S +NLD rat groups (1-way ANOVA, F[3,23] = 9.353; P = .0005; post hoc Tukey; P < .001; 6 rats per group). Pretreatment with NLD decreased antinociceptive effect of M6S in PPT test by 33.6 g (95% CI, 1.78-65.4). ANOVA indicates analysis of variance; CI, confidence interval; M6S, morphine-6-O-sulfate; NLD, naltrindole; OR, opioid receptor; PPT, paw pressure threshold; RM, repeated-measures.
www.anesthesia-analgesia.org ANESTHESIA & ANALGESIA with the differential involvement of specific subtypes of ORs in modulating the activity of a given pain pathway. 4, 30, 31 In agreement with studies reported in κ-OR knockout mice, 39 results from the current studies using the κ-OR antagonist nor-BNI suggest these receptors play no role in the control of somatic pain sensations (PST, PPT, and HPT). In contrast, with regard to δ-ORs, our results suggest these receptors are critical for controlling superficial pricking, moderate for superficial burning, and minor for deep pressure-evoked pain.
Our finding that the PST pathway in rats is almost under exclusive control by the δ-OR system is in agreement with reports that mouse skin mechanoreceptors express δ-but not μ-ORs and that the mouse paw von Frey filament withdrawal threshold is sensitive to δ-but not μ-ORselective agonists. 40, 41 This finding is also in agreement with observations that pinprick hyperalgesia in humans examined in experimental skin inflammation and postsurgical pain models respond poorly to μ-OR agonists. [42] [43] [44] Similarly, the finding that the selective δ-opioid antagonist NLD blocks approximately 50% of M6S-mediated antinociception in the HPT test ( Figure 2C ) agrees with previous studies demonstrating equivalent involvement of δ and μ-ORs in the control of pain associated with radiant heat in the TFL test. 14, 16, 18, 45 However, reports that TFL in mice is sensitive to μ but not δ-OR-selective agonists should be noted. 40, 41 Thus, additional studies will be required to 3), respectively. The antinociceptive effect of M6S administered to rats chronically treated with morphine was not statistically different from its effects produced on any of the days studied in chronic M6S treatment experiments (dark gray bar, compare with data presented by filled circles; 1-way RM ANOVA; F[3,23] = 2.539; P = .096; mean effect differences never exceeded 4.3 g [95% CI, −1.1 to 9.8], the value observed when action of M6S in morphine-tolerant rats was compared with its action on day 3 of chronic treatment). C, Percent maximum effect on PST for morphine and M6S alone or after pretreatment with δ-or κ-OR-specific antagonists: naltrindole (NLD, 1 mg/kg, IP) or norbinaltorphimine (nor-BNI, 5 mg/kg, IP). Asterisks indicates statistically significant difference between M6S and M6S +NLD rat groups (1-way ANOVA F[2,17] = 56.55; P < .01; post hoc Tukey test P < .01; 6 rats per group). Mean effect differences from control were 95.8% (95% CI, 70.4-121.3) for M6S + NLD and 12.5% (95% CI, −13.0 to 38.0) for M6S + nor-BNI group of rats. ANOVA indicates analysis of variance; BNI, binaltorphimine; CI, confidence interval; M6S, morphine-6-O-sulfate; NLD, naltrindole; OR, opioid receptor; PST, pinprick sensitivity threshold; RM, repeated-measures. Deep aching pain is associated with activation of C-or Aδ (small nonmyelinated and thinly myelinated fibers, respectively) muscle afferents. These afferents serve both as ergoand nociceptors. 47 Studies of the rat exercise pressor reflex (homeostatic control, ergo-receptor function) suggest that muscle C-and Aδ-afferents express μ-and δ-ORs, 48, 49 respectively. The current study failed to detect substantial input of δ-ORs for control of pain in the PPT test in normal rats ( Figure 4C ). The central role of μ-ORs in the control of deep muscle pain is also supported by studies on the association of human OR gene polymorphisms with PPT 50 and by observations of the involvement of μ-OR pathways in fibromyalgia. 51 However, our data also suggest that during chronic treatment with M6S, the involvement of δ-ORs in controlling pain measured in the PPT test may increase from 5% to 60% over time ( Figure 4B, C) . These observations agree with reports that chronic activation of μ-ORs (by M6S in the current studies) leads to recruitment of δ-ORs to the neuronal membrane. [34] [35] [36] Thus, it is possible that although in acute treatment experiments M6S acts in the PPT test via μ-ORs only, after a few days of chronic treatment in the same test, M6S may realize its potential as a mixed μ/δ-OR agonist. This could explain the observed "recovery" from tolerance in the current study of daily treatment with M6S in rats in the PPT test ( Figure  4B ). Tolerance is delayed in response to mixed μ/δ-OR agonists when compared with μ-OR agonists. 15, 16, 18 Use of multiple comparisons and relatively small sample size in many of the experiments in this study constitute a potential limitation for interpretation of the results obtained and call for further evaluation of M6S and mechanisms involved in its antinociceptive effects. However, although perhaps providing additional important information, it is our belief that such future studies will not considerably alter the significance or the main conclusions derived from the current study.
CONCLUSIONS
This study is the first to demonstrate that M6S exhibits a number of properties that indicate that this morphine derivative is likely superior to morphine for treatment of pain. This conclusion is based on the increased antinociceptive potency, efficacy, and duration of action and the improved tolerance profile of M6S when compared with morphine. Thus, M6S has potential as a safe and efficacious alternative to traditional μ-OR agonists such as morphine for treatment of both acute and chronic multimodal pain. Furthermore, M6S may be a good candidate for opioid rotation in morphine-tolerant subjects. The potential ability of M6S to act as a mixed μ/δ-OR agonist appears to be a likely key determinant of differences in antinociception produced by M6S and morphine in the pain modalities examined in this current study. E
